Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

2018 Long Term Incentive Plan awards

23 Oct 2018 07:00

RNS Number : 8232E
Ideagen PLC
23 October 2018
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

2018 Long Term Incentive Plan awards

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, announces the award of 1,200,000 share options over the Company's ordinary shares of 1p each ("Ordinary Shares") to Ben Dorks, Chief Executive Officer, under the Company's 2018 Long Term Incentive Plan ("2018 LTIP").

 

On 23 March 2017, the Company made awards to certain directors of share options pursuant to the terms of the 2017 Long Term Incentive Plan ("2017 LTIP").

 

These share options were issued with the principal aim, which has now been achieved, of becoming fully exercisable on the Company achieving a share price of 136 pence, which represented a doubling of the share price from the 68 pence condition set in the previous Long Term Incentive Plan.

 

The principles underpinning the 2018 LTIP are similar to the 2017 LTIP insofar as the awards will be subject to the following challenging performance criteria: one half become eligible to vest on the Company's share price reaching 196 pence over 30 consecutive business days with the remainder becoming eligible to vest on the Company's share price reaching 259 pence over 30 consecutive business days.

 

Options issued pursuant to the 2018 LTIP will not vest until the third anniversary of the grant date. Thereafter, any Ordinary Shares issued in respect of the exercise of any of these options cannot be sold until the fourth anniversary of the grant date except to meet the taxation costs arising on the exercise of those options. They are also subject to continued service throughout as well as the aforementioned achievement of specific performance targets relating to the Company's share price. These options each have an exercise price of 1 penny per Ordinary Share. 

 

Following the award of these options, there are now 9,283,333 options over Ordinary Shares in issue representing 4.2% of the issued share capital of the Company.

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

Ben Dorks, Chief Executive Officer

Graeme Spenceley, Finance Director

finnCap Limited

020 7220 0500

Stuart Andrews/Henrik Persson/James Thompson (Nomad)

Alice Lane (ECM)

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit, Pentana Performance and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 3,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com.

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Ben Dorks

2.

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Ideagen plc

b)

LEI:

213800KS1MLITOVNYC85

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 penny each

 

GB00B0CM0C50

b)

Nature of the transaction:

Award of share options

c)

Price(s) and volume(s):

 1,200,000 options over ordinary shares of 1 pence each awarded

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 1,200,000 options over ordinary shares of 1 pence each awarded

 

e)

Date of the transaction:

22 October 2018

f)

Place of the transaction:

Off market transaction

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMMZGMZFGRZZ
Date   Source Headline
14th Oct 20215:46 pmRNSIssue of new shares under the SIP
14th Oct 20217:00 amRNSSale of Pentana Compliance
11th Oct 20212:25 pmRNSNotice of AGM
1st Oct 20213:15 pmRNSTotal Voting Rights
1st Oct 20217:00 amRNSChange of Auditor
24th Sep 20219:37 amRNSIssue of Shares, PDMR Dealing & TVR
13th Sep 20214:50 pmRNSExercise of Options and Total Voting Rights
10th Sep 20216:05 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSTotal Voting Rights
31st Aug 20219:32 amRNSHolding(s) in Company
26th Aug 20217:00 amRNSPDMR Dealing and Total Voting Rights
11th Aug 20212:02 pmRNSIssue of new shares under the SIP and TVR
11th Aug 20217:00 amRNSExercise of Options and Total Voting Rights
23rd Jul 20214:54 pmRNSPDMR Dealing and Total Voting Rights
22nd Jul 20217:00 amRNSFinal Results
20th Jul 20212:03 pmRNSIssue of new shares under the SIP
19th Jul 20217:00 amRNSTwo highly complementary strategic acquisitions
15th Jul 20214:17 pmRNSExercise of share options and Total Voting Rights
16th Jun 20217:00 amRNSIssue of new shares under the SIP
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:36 pmRNSPrice Monitoring Extension
21st May 20217:00 amRNSDirector/PDMR Shareholding
13th May 20217:00 amRNSPre-Close Trading Update and Board Change
28th Apr 20217:00 amRNSDirector Dealings and Total Voting Rights
14th Apr 202112:40 pmRNSIssue of Shares, PDMR Dealing & TVR
16th Mar 20213:33 pmRNSIssue of new shares under the SIP and TVR
9th Mar 20217:00 amRNSAcquisition of Qualtrax
26th Feb 20211:49 pmRNSHolding(s) in Company
25th Feb 20214:00 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSHolding(s) in Company
23rd Feb 20217:00 amRNSPDMR Dealing and Total Voting Rights
16th Feb 20215:15 pmRNSIssue of Equity & Total Voting Rights
12th Feb 20217:00 amRNSDirector/PDMR Dealings
3rd Feb 20219:35 amRNSExtension to 2018 LTIP Awards
26th Jan 20217:00 amRNSSuccession of Chairman
26th Jan 20217:00 amRNSUnaudited Interim Results
25th Jan 20214:26 pmRNSH1 Results Presentation
22nd Jan 20217:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
30th Dec 20207:21 amRNSCompletion of Huddle Acquisition
23rd Dec 202011:30 amRNSAcquisition of Huddle
22nd Dec 20202:04 pmRNSHolding(s) in Company
18th Dec 202012:56 pmRNSIssue of Shares & Director/PDMR Shareholding
9th Dec 20207:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20204:53 pmRNSPrimaryBid.com Offer
8th Dec 20204:50 pmRNSProposed Fundraise of £48.7 million
20th Nov 20203:40 pmRNSIssue of Equity, PDMR Dealing and TVR
17th Nov 202012:05 pmRNSChange of Registered Office
13th Nov 20203:51 pmRNSPDMR Shareholding and Exercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.